US Bioservices to exclusively dispense Diacomit
US Bioservices, a specialty pharmacy that is a part of AmerisourceBergen, announced Wednesday that it has been selected by Biocodex SAS to exclusively dispense Diacomit (stiripentol).
The Food and Drug Administration approved Diacomit on Aug. 20, 2018 for the treatment of seizures associated with Dravet syndrome in patients two years of age and older taking Clobazam.
Diacomit is approved by the FDA in two formulations – capsules and powder for oral suspension.
Dravet syndrome, also known as severe myoclonic epilepsy in infancy, is an orphan disease considered one of the most intractable forms of epilepsy, with first seizures occurring during the first year of life. DS is characterized by severe epilepsy, psychomotor retardation and a high mortality rate reported in up to 21% of these patients. DS is thought to affect approximately 2,800 patients aged 2 to18 years in the United States, and Diacomit addresses key unmet medical needs in this poorly serviced population experiencing a catastrophic, life-threatening condition.
"US Bioservices is proud to partner with Biocodex to bring this innovative treatment to patients affected by Dravet syndrome,” US Bioservices president Angela Ward said. “Because of our unmatched experience in rare disease, we understand the clinical expertise and coordination required to support the specialized needs of patients and their caregivers. We welcome the opportunity to facilitate access to treatment and provide clinically-coordinated care for patients who are prescribed Diacomit.”
The Food and Drug Administration approved Diacomit on Aug. 20, 2018 for the treatment of seizures associated with Dravet syndrome in patients two years of age and older taking Clobazam.
Diacomit is approved by the FDA in two formulations – capsules and powder for oral suspension.
Dravet syndrome, also known as severe myoclonic epilepsy in infancy, is an orphan disease considered one of the most intractable forms of epilepsy, with first seizures occurring during the first year of life. DS is characterized by severe epilepsy, psychomotor retardation and a high mortality rate reported in up to 21% of these patients. DS is thought to affect approximately 2,800 patients aged 2 to18 years in the United States, and Diacomit addresses key unmet medical needs in this poorly serviced population experiencing a catastrophic, life-threatening condition.
"US Bioservices is proud to partner with Biocodex to bring this innovative treatment to patients affected by Dravet syndrome,” US Bioservices president Angela Ward said. “Because of our unmatched experience in rare disease, we understand the clinical expertise and coordination required to support the specialized needs of patients and their caregivers. We welcome the opportunity to facilitate access to treatment and provide clinically-coordinated care for patients who are prescribed Diacomit.”